Given the urgent need for new therapeutic options for osteosarcoma, particularly in patients with metastatic disease, our results support the exploration of MCL-1-targeted treatments to improve patient outcomes in this challenging cancer type. This evidence concerns the gene MCL1 and osteosarcoma.